Table 4.

Influence of human urine on the in vitro activities of ciprofloxacin (CPFX) and sparfloxacin (SPFX) against E. coliNIHJ JC-2 and P. aeruginosa ATCC 27853

Subject no.NH4Cl treatmentNaHCO3 treatment
pHConcn [mg/liter (fold increase)] of:MIC [μg/ml (fold increase)] for:pHConcn [mg/liter (fold increase)] of:MIC [μg/ml (fold increase)] for:
Ca2+Mg2+E. coli NIHJ JC-2P. aeruginosa ATCC 27853Ca2+Mg2+E. coli NIHJ JC-2P. aeruginosa ATCC 27853
CPFXSPFXCPFXSPFXCPFXSPFXCPFXSPFX
15.36320 (4)145 (4.3)0.25 (4)0.25 (4)0.1252 (2)6.2886610.0630.0630.50 (2)1
25.40220 (4)120 (1.2)0.125 (4)0.125 (4)0.125 (1)2 (4)6.37581000.0310.0310.1250.50
35.27200 (2)800.50 (8)0.50 (8)0.125 (2)2 (4)6.1097105 (1.3)0.0630.0630.0630.50
46.39200 (2)135 (2.5)0.063 (4)0.063 (4)0.25 (2)0.50 (4)7.7843530.0160.0160.1250.125
56.03240 (2)145 (1)0.125 (2)0.25 (4)0.1252 (4)7.282251100.0630.0630.50 (4)0.50
66.12200 (2)54 (1)0.50 (8)0.50 (8)0.25 (1)2 (1)7.1413440.0630.0630.252
76.13270 (7)130 (1.3)0.125 (1)0.25 (1)0.25 (1)2 (1)7.43411000.1250.250.252
85.7980 (1)70 (1)0.125 (2)0.125 (2)0.251 (2)6.3579850.0630.0630.50 (2)0.50
95.3056 (1)33 (2)0.50 (31)0.50 (31)0.50 (1)2 (4)8.0136180.0160.0160.500.25
 Mean (SD)5.75 (0.43)178.4 (97)101.3 (40.1)6.97 (0.71)75.3 (58.6)75.1 (30.5)
 Range5.27–6.3956–32033–1450.063–0.500.063–0.500.125–0.500.50–26.84–8.113–22518–1100.016–0.1250.016–0.250.125–0.500.125–2